The estimated Net Worth of Capital, Llc Braslyn Ltd. B... is at least $184 million dollars as of 16 November 2017. Capital B owns over 400,000 units of Mirati Therapeutics Inc stock worth over $184,081,204 and over the last 7 years Capital sold MRTX stock worth over $0.
Capital has made over 1 trades of the Mirati Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Capital bought 400,000 units of MRTX stock worth $5,200,000 on 16 November 2017.
The largest trade Capital's ever made was buying 400,000 units of Mirati Therapeutics Inc stock on 16 November 2017 worth over $5,200,000. On average, Capital trades about 400,000 units every 0 days since 2017. As of 16 November 2017 Capital still owns at least 3,135,966 units of Mirati Therapeutics Inc stock.
You can see the complete history of Capital B stock trades at the bottom of the page.
Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over $179,669,845 worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth $186,410,608 . The most active insiders traders include Healthcare Master Fund Ltd ..., Capital Advisors Llc Aghaza... et Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $5,885,145. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth $94,255.
mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.
Mirati Therapeutics Inc executives and other stock owners filed with the SEC include: